{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:55:49Z","timestamp":1791327349213,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s10072-023-06683-2","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T12:02:56Z","timestamp":1677240176000},"page":"2455-2463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study"],"prefix":"10.1007","volume":"44","author":[{"given":"Hyoung Cheol","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soohyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-4682","authenticated-orcid":false,"given":"Byung-Kun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"issue":"1","key":"6683_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","journal-title":"Cephalalgia"},{"issue":"3","key":"6683_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3988\/jcn.2014.10.3.236","volume":"10","author":"JW Park","year":"2014","unstructured":"Park JW, Moon HS, Kim JM, Lee KS, Chu MK (2014) Chronic daily headache in Korea: prevalence, clinical characteristics, medical consultation and management. J Clin Neurol 10(3):236\u2013243. https:\/\/doi.org\/10.3988\/jcn.2014.10.3.236","journal-title":"J Clin Neurol"},{"issue":"11","key":"6683_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBDH Collaborators","year":"2018","unstructured":"GBDH Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):954\u2013976. https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"issue":"4","key":"6683_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37(4):631\u2013649. https:\/\/doi.org\/10.1016\/j.ncl.2019.06.001","journal-title":"Neurol Clin"},{"issue":"2","key":"6683_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11910-010-0175-6","volume":"11","author":"ME Bigal","year":"2011","unstructured":"Bigal ME, Lipton RB (2011) Migraine chronification. Curr Neurol Neurosci Rep 11(2):139\u2013148. https:\/\/doi.org\/10.1007\/s11910-010-0175-6","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"6683_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11916-010-0157-z","volume":"15","author":"AN Manack","year":"2011","unstructured":"Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 15(1):70\u201378. https:\/\/doi.org\/10.1007\/s11916-010-0157-z","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"6683_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneur.61.4.490","volume":"61","author":"SD Silberstein","year":"2004","unstructured":"Silberstein SD, Neto W, Schmitt J, Jacobs D, Group M-S (2004) Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61(4):490\u20135. https:\/\/doi.org\/10.1001\/archneur.61.4.490","journal-title":"Arch Neurol"},{"issue":"8","key":"6683_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jama.291.8.965","volume":"291","author":"JL Brandes","year":"2004","unstructured":"Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J et al (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291(8):965\u2013973. https:\/\/doi.org\/10.1001\/jama.291.8.965","journal-title":"JAMA"},{"issue":"7","key":"6683_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793\u2013803. https:\/\/doi.org\/10.1177\/0333102410364676","journal-title":"Cephalalgia"},{"issue":"7","key":"6683_CR10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804\u2013814. https:\/\/doi.org\/10.1177\/0333102410364677","journal-title":"Cephalalgia"},{"issue":"5","key":"6683_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"issue":"6","key":"6683_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"issue":"22","key":"6683_CR13","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"issue":"24","key":"6683_CR14","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221. https:\/\/doi.org\/10.1212\/WNL.0000000000006640","journal-title":"Neurology"},{"issue":"13","key":"6683_CR15","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"issue":"8","key":"6683_CR16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454. https:\/\/doi.org\/10.1177\/0333102418779543","journal-title":"Cephalalgia"},{"issue":"10","key":"6683_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, Lainez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9","journal-title":"Lancet Neurol"},{"issue":"2","key":"6683_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61(2):363\u2013372. https:\/\/doi.org\/10.1111\/head.14032","journal-title":"Headache"},{"issue":"3","key":"6683_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ane.13472","volume":"144","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A (2021) Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand 144(3):325\u2013333. https:\/\/doi.org\/10.1111\/ane.13472","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"6683_CR20","doi-asserted-by":"publisher","first-page":"e2260","DOI":"10.1002\/brb3.2260","volume":"11","author":"C Baraldi","year":"2021","unstructured":"Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S (2021) Predictors of response to erenumab after 12 months of treatment. Brain Behav 11(8):e2260. https:\/\/doi.org\/10.1002\/brb3.2260","journal-title":"Brain Behav"},{"issue":"10","key":"6683_CR21","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferrus","year":"2021","unstructured":"Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268(10):3789\u20133798. https:\/\/doi.org\/10.1007\/s00415-021-10523-8","journal-title":"J Neurol"},{"issue":"1","key":"6683_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-021-01267-x","volume":"22","author":"R Belvis","year":"2021","unstructured":"Belvis R, Irimia P, Pozo-Rosich P, Gonzalez-Oria C, Cano A, Viguera J et al (2021) MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. J Headache Pain 22(1):74. https:\/\/doi.org\/10.1186\/s10194-021-01267-x","journal-title":"J Headache Pain"},{"issue":"1","key":"6683_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain 22(1):120. https:\/\/doi.org\/10.1186\/s10194-021-01328-1","journal-title":"J Headache Pain"},{"issue":"1","key":"6683_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F et al (2021) Association between response to triptans and response to erenumab: real-life data. J Headache Pain 22(1):1. https:\/\/doi.org\/10.1186\/s10194-020-01213-3","journal-title":"J Headache Pain"},{"key":"6683_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-015-0552-2","volume":"16","author":"JG Seo","year":"2015","unstructured":"Seo JG, Park SP (2015) Validation of the Patient Health Questionnaire-9 (PHQ-9) and PHQ-2 in patients with migraine. J Headache Pain 16:65. https:\/\/doi.org\/10.1186\/s10194-015-0552-2","journal-title":"J Headache Pain"},{"key":"6683_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s10194-015-0583-8","volume":"16","author":"JG Seo","year":"2015","unstructured":"Seo JG, Park SP (2015) Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine. J Headache Pain 16:97. https:\/\/doi.org\/10.1186\/s10194-015-0583-8","journal-title":"J Headache Pain"},{"issue":"7","key":"6683_CR27","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1212\/WNL.0000000000010000","volume":"95","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Cohen JM, Gandhi SK, Yang R, Yeung PP, Buse DC (2020) Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. Neurology 95(7):e878\u2013e888. https:\/\/doi.org\/10.1212\/WNL.0000000000010000","journal-title":"Neurology"},{"issue":"9","key":"6683_CR28","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J et al (2019) Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia 39(9):1075\u20131085. https:\/\/doi.org\/10.1177\/0333102419858355","journal-title":"Cephalalgia"},{"issue":"1","key":"6683_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1","journal-title":"J Headache Pain"},{"issue":"20","key":"6683_CR30","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2021","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U et al (2021) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92(20):e2309\u2013e2320. https:\/\/doi.org\/10.1212\/WNL.0000000000007497","journal-title":"Neurology"},{"issue":"1","key":"6683_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114. https:\/\/doi.org\/10.1186\/s10194-020-01173-8","journal-title":"J Headache Pain"},{"issue":"1","key":"6683_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"HC Diener","year":"2021","unstructured":"Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML et al (2021) Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. Headache 61(1):125\u2013136. https:\/\/doi.org\/10.1111\/head.14036","journal-title":"Headache"},{"issue":"3","key":"6683_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0333102420966658","volume":"41","author":"DW Dodick","year":"2021","unstructured":"Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J et al (2021) Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41(3):340\u2013352. https:\/\/doi.org\/10.1177\/0333102420966658","journal-title":"Cephalalgia"},{"issue":"5","key":"6683_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/0333102411431309","volume":"32","author":"J Olesen","year":"2012","unstructured":"Olesen J (2012) Detoxification for medication overuse headache is the primary task. Cephalalgia 32(5):420\u2013422. https:\/\/doi.org\/10.1177\/0333102411431309","journal-title":"Cephalalgia"},{"issue":"9","key":"6683_CR35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaneurol.2020.1179","volume":"77","author":"LN Carlsen","year":"2020","unstructured":"Carlsen LN, Munksgaard SB, Nielsen M, Engelstoft IMS, Westergaard ML, Bendtsen L et al (2020) Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol 77(9):1069\u20131078. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1179","journal-title":"JAMA Neurol"},{"key":"6683_CR36","doi-asserted-by":"publisher","first-page":"251581632110266","DOI":"10.1177\/25158163211026646","volume":"4","author":"H Salem-Abdou","year":"2021","unstructured":"Salem-Abdou H, Simonyan D, Puymirat J (2021) Identification of predictors of response to erenumab in a cohort of patients with migraine. Cephalalgia Reports 4:25158163211026650. https:\/\/doi.org\/10.1177\/25158163211026646","journal-title":"Cephalalgia Reports"},{"issue":"1","key":"6683_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1):32. https:\/\/doi.org\/10.1186\/s10194-020-01102-9","journal-title":"J Headache Pain"},{"issue":"9","key":"6683_CR38","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212","journal-title":"JAMA Neurol"},{"key":"6683_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-016-0616-y","volume":"17","author":"OO Yalin","year":"2016","unstructured":"Yalin OO, Uluduz D, Ozge A, Sungur MA, Selekler M, Siva A (2016) Phenotypic features of chronic migraine. J Headache Pain 17:26. https:\/\/doi.org\/10.1186\/s10194-016-0616-y","journal-title":"J Headache Pain"},{"key":"6683_CR40","doi-asserted-by":"publisher","first-page":"705276","DOI":"10.3389\/fpain.2021.705276","volume":"2","author":"TJ Mungoven","year":"2021","unstructured":"Mungoven TJ, Henderson LA, Meylakh N (2021) Chronic migraine pathophysiology and treatment: a review of current perspectives. Front Pain Res (Lausanne) 2:705276. https:\/\/doi.org\/10.3389\/fpain.2021.705276","journal-title":"Front Pain Res (Lausanne)"},{"issue":"Suppl 1","key":"6683_CR41","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.pain.2013.07.021","volume":"154","author":"R Noseda","year":"2013","unstructured":"Noseda R, Burstein R (2013) Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain 154(Suppl 1):S44-53. https:\/\/doi.org\/10.1016\/j.pain.2013.07.021","journal-title":"Pain"},{"key":"6683_CR42","doi-asserted-by":"publisher","first-page":"805334","DOI":"10.3389\/fneur.2021.805334","volume":"12","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, Gerard P (2021) Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol 12:805334. https:\/\/doi.org\/10.3389\/fneur.2021.805334","journal-title":"Front Neurol"},{"issue":"10","key":"6683_CR43","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1111\/head.13970","volume":"60","author":"TA Smitherman","year":"2020","unstructured":"Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D\u2019Souza DN et al (2020) Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and\/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies. Headache 60(10):2202\u20132219. https:\/\/doi.org\/10.1111\/head.13970","journal-title":"Headache"},{"issue":"6","key":"6683_CR44","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/head.14123","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Fofi L, Grazzi L, Vernieri F, Camarda C, Torelli P et al (2021) Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: a real-life perspective from the Italian chROnic migraiNe (IRON) project. Headache 61(6):936\u2013950. https:\/\/doi.org\/10.1111\/head.14123","journal-title":"Headache"},{"issue":"1","key":"6683_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-021-01333-4","volume":"22","author":"S Bottiroli","year":"2021","unstructured":"Bottiroli S, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M et al (2021) Psychological predictors of negative treatment outcome with erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain 22(1):114. https:\/\/doi.org\/10.1186\/s10194-021-01333-4","journal-title":"J Headache Pain"},{"issue":"1","key":"6683_CR46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-022-01435-7","volume":"23","author":"J Liu","year":"2022","unstructured":"Liu J, Wang G, Dan Y, Liu X (2022) CGRP and PACAP-38 play an important role in diagnosing pediatric migraine. J Headache Pain 23(1):68. https:\/\/doi.org\/10.1186\/s10194-022-01435-7","journal-title":"J Headache Pain"},{"issue":"6","key":"6683_CR47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.npep.2013.10.010","volume":"47","author":"EA Kaiser","year":"2013","unstructured":"Kaiser EA, Russo AF (2013) CGRP and migraine: could PACAP play a role too? Neuropeptides 47(6):451\u2013461. https:\/\/doi.org\/10.1016\/j.npep.2013.10.010","journal-title":"Neuropeptides"},{"issue":"1","key":"6683_CR48","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/ene.15563","volume":"30","author":"F Vernieri","year":"2023","unstructured":"Vernieri F, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C et al (2023) Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study. Eur J Neurol 30(1):224\u2013234. https:\/\/doi.org\/10.1111\/ene.15563","journal-title":"Eur J Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06683-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T04:04:31Z","timestamp":1686369871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06683-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6683"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06683-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Byung-Kun Kim served on Lundbeck\u2019s advisory board. He has received honoraria as a moderator and speaker from Lundbeck, AbbVie, Pfizer, Eli Lilly, Teva, Yuyu Pharm, and SK Pharm and has been the principal investigator of the clinical trials sponsored by Eli-Lilly, Novartis, Lundbeck, Teva, AbbVie, and Ildong Pharm. He received personal fees from the National Pension Service and Center for New Health Technology Assessment outside the submitted work. Hyoung Cheol Lee and Soohyun Cho declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}